Targeting IL-33 to improve disease outcome has been promising in other neurodegenerative diseases such as experimental autoimmune encephalomyelitis (EAE) and Alzheimer’s [92,93]; therefore, investigating the IL-33:ST2 axis in skeletal muscle pathology and glial toxicity in ALS might be beneficial. This evidence concerns the gene IL33 and experimental autoimmune encephalomyelitis.